|
Getting wise to the influenza virus' tricks
May 05, 2008A high-resolution image of an influenza virus protein opens the way to design new anti-viral drugs
Influenza is currently a grave concern for governments and health organisations around the world. The worry is the potential for highly virulent bird flu strains, such as H5N1, to develop the ability to infect humans easily. New drugs and vaccines to halt the spread of the virus are badly needed. Now one of the tactics used by influenza virus to take over the machinery of infected cells has been laid bare by structural biologists at the European Molecular Biology Laboratory (EMBL) and the joint Unit of Virus Host-Cell Interaction of EMBL, the University Joseph Fourier and National Centre for Scientific Research (CNRS), in Grenoble, France. In the current issue of Nature Structural and Molecular Biology they publish a high-resolution image of a key protein domain whose function is to allow the virus to multiply by hijacking the host cell protein production machinery. The findings open the way for the design of new drugs to combat future influenza pandemics.
Upon infection the influenza virus starts multiplying in the cells of its host. One protein that is crucial in this process is the viral polymerase - the enzyme that copies its genetic material and helps to produce more viruses. One component of the polymerase, called PB2, plays a key role in stealing an important tag from host cell RNA molecules to direct the protein production machinery towards the synthesis of viral proteins. Researchers of the groups of Stephen Cusack and Darren Hart at EMBL Grenoble have identified the PB2 domain responsible for binding the tag, produced crystals of it and examined them with the powerful X-ray beams of the European Synchrotron Radiation Facility (ESRF).
"Viruses are masters of cunning when it comes to hijacking the normal functioning of the host cell. The influenza virus steals a password from host messenger RNAs, molecules that carry the instructions for protein production, and uses it to gain access to the cell's protein-making machinery for its own purposes," says Cusack.
The password is a short extra piece of RNA, a modified RNA base called a 'cap', which must be present at the beginning of all messenger RNAs (mRNAs) to direct the cell's protein-synthesis machinery to the starting point. The viral polymerase binds to host cell mRNA via its cap, cuts the cap off and adds it to the beginning of its own mRNA - a process known as 'cap snatching'. The capped viral mRNA can then be recognised by the host cell machinery allowing viral proteins to be made, at the expense of host cell proteins.
The atomic resolution image the EMBL scientists generated of a PB2 domain bound to a cap reveals for the first time the individual amino acids responsible for recognising this special structure. The central interaction is a sandwich with two PB2 amino acids stacking either side of the cap. Whilst this recognition mechanism is similar to other cap-binding proteins, its structural details are distinct. Collaborators at the Centro Nacional de Biotecnologia in Madrid showed that disruption of the PB2 cap-binding site prevents the influenza virus from replicating.
"These findings suggest that the PB2 cap-binding site is a very promising target for anti-influenza drugs," Hart says. "Our new structural insights will help us design mimics of the cap that would inhibit viral replication and hence reduce the spread of virus and the severity of the infection."
European Molecular Biology Laboratory
"Viruses are masters of cunning when it comes to hijacking the normal functioning of the host cell. The influenza virus steals a password from host messenger RNAs, molecules that carry the instructions for protein production, and uses it to gain access to the cell's protein-making machinery for its own purposes," says Cusack.
The password is a short extra piece of RNA, a modified RNA base called a 'cap', which must be present at the beginning of all messenger RNAs (mRNAs) to direct the cell's protein-synthesis machinery to the starting point. The viral polymerase binds to host cell mRNA via its cap, cuts the cap off and adds it to the beginning of its own mRNA - a process known as 'cap snatching'. The capped viral mRNA can then be recognised by the host cell machinery allowing viral proteins to be made, at the expense of host cell proteins.
The atomic resolution image the EMBL scientists generated of a PB2 domain bound to a cap reveals for the first time the individual amino acids responsible for recognising this special structure. The central interaction is a sandwich with two PB2 amino acids stacking either side of the cap. Whilst this recognition mechanism is similar to other cap-binding proteins, its structural details are distinct. Collaborators at the Centro Nacional de Biotecnologia in Madrid showed that disruption of the PB2 cap-binding site prevents the influenza virus from replicating.
"These findings suggest that the PB2 cap-binding site is a very promising target for anti-influenza drugs," Hart says. "Our new structural insights will help us design mimics of the cap that would inhibit viral replication and hence reduce the spread of virus and the severity of the infection."
European Molecular Biology Laboratory
Influenza News and Current Influenza Events RSSPandemic flu: Most nursing homes don't have a plan
If an influenza pandemic hits the United States, acute care hospitals are likely to be overwhelmed. Nursing homes may then be expected to assist with the patient overflow, but a new study in the Journal of the American Medical Association suggests that many are not prepared for such a task.
Study outlines measures to limit effects of pandemic flu on nursing homes
The greatest danger in a pandemic flu outbreak is that it could spread quickly and devastate a broad swath of people across the United States before there is much of a chance to react. The result could be a nation brought to its knees by a disease run rampant.
Booster vaccination may help with possible future avian influenza pandemic
New evidence suggests that a booster vaccination against H5N1 avian influenza given years after initial vaccination with a different strain may prove useful in controlling a potential future pandemic. The study is published in the August 1 issue of The Journal of Infectious Diseases, now available online.
Newly described 'dragon' protein could be key to bird flu cure
Scientists and researchers have taken a big step closer to a cure for the most common strain of avian influenza, or "bird flu," the potential pandemic that has claimed more than 200 lives and infected nearly 400 people in 14 countries since it was identified in 2003.
Mobilizing white blood cells to the lung: New discovery could lead to an improved influenza vaccine
Findings just published in the scientific journal Immunity by researchers at the Trudeau Institute shed new light on how a previously-unknown messaging mechanism within the human immune system prompts specific influenza-fighting cells to the lung airways during an infection.
Fruit fly gene study could yield new flu treatments
As they design new drugs to fight off influenza, scientists may not need to attack the virus directly. Instead, they may be able to stave off infection by targeting one of more than 100 proteins inside host cells on which the virus depends.
Political borders, health-care issues complicate pandemic planning
Panic, staffing issues and geographic boundaries are some of the challenges that public health experts need to address as they plan for a possible influenza pandemic, according to a new report from Purdue University.
Penn animal study identifies new DNA weapon against avian flu
Researchers at the University of Pennsylvania School of Medicine have identified a potential new way to vaccinate against avian flu.
Pitt Team Receives $2.5 Million to Simulate and Analyze Brain, Immune System Activity and Apply Math to Medical Problems
In an effort to promote the application of mathematics to medical treatment, researchers in the University of Pittsburgh's Department of Mathematics will undertake a $2.5 million project to create models of how the brain and immune system function and change over time in response to certain illnesses, infections, and treatment.
European businesses not properly advised on how to prepare for flu pandemic
A new report entitled Business Continuity Planning and Pandemic Influenza in Europe, published by the London School of Hygiene & Tropical Medicine (LSHTM), has found huge gaps and differences across Europe in the level of advice given to businesses to prepare for a possible influenza pandemic.
More Influenza News Articles
 | The Great Influenza: The story of the deadliest pandemic in history by John M. Barry |
 | The Last Town on Earth: A Novel by Thomas Mullen |
 | The Germ Freak's Guide to Outwitting Colds and Flu: Guerilla Tactics to Keep Yourself Healthy at Home, at Work and in the World by Charles Gerba, Allison Janse |
 | Flu: The Story Of The Great Influenza Pandemic by Gina Kolata |
 | Darkest Hour (Heartland, Book 13) by Lauren Brooke |
 | Horse Health & Nutrition For Dummies (For Dummies (Pets)) by Audrey Pavia, Kate, DVM, CVA Gentry-Running |
 | America's Forgotten Pandemic: The Influenza of 1918 by Alfred W. Crosby |
 | Marven of the Great North Woods by Kathryn Lasky |
 | Wickett's Remedy: A Novel by Myla Goldberg |
 | Armageddon Strain (The Countdown) by Sharon K. Gilbert |
| © 2008 BrightSurf.com |